New glycated hemoglobin antibody as long term diabetic biomarker
Glycation of proteins in blood circulation occurs naturally when circulating sugar is metabolized in the body. Glucose is known to attach to hemoglobin in the bloodstream to form glycated hemoglobin (HbA1c).
Glucose and Glycated hemoglobin (Bb1Ac) as diabetic biomarkers
Hemoglobin is a long-living blood protein complex (around 120 days). Such stability can be used to measure blood HbA1c and thus, indirectly monitor average blood glucose levels during a longer period of time than daily glycemia measurements.
A possible allegory would be to compare Hb1Ac measurements with a movie covering a period of several weeks (average hyperglycemia), and glucose blood testing with instant photography (punctual glycemia with possible fluctuation over the day).
Glycemia and Hb1Ac measurements are complementary data. They can help diagnose, monitor and stratify patients with diabetes (eg. American Diabetes Association, World Health Organization…). It might also help in the design of personalized therapies. Diabetes.co.uk mentions 2 clinical studies which show that improving HbA1c by 1%, might reduce risks of microvascular complications by 25% for patients with type 1 diabetes or type 2 diabetes.
Immunoassays are robust antibody-based quantitative methods. They are used to measure glycated hemoglobin HbA1c concentration expressed as a percentage of HbA1c to total hemoglobin.
These immuno-assays require well characterized and reliable primary antibodies.
A new hybridoma clone (75C9) specific for HbA1c has been released.
This 75C9 clone has been validated to measure Hb1Ac as a diabetic biomarker by direct and sandwich ELISA and complements the clone Hb6 which reacts with both unmodified and glycated hemoglobin.
Want to develop hemoglobin-specific ummunoassays with reliable monoclonals?
This is something the experts at tebu-bio can help with, you might like to get in touch with them for solutions regarding your research projects.